Oncological outcomes of testicular cancer patients: 10 years of experiences resulting from a single university-based hospital
Article Category: Research Article
Published Online: May 03, 2022
Page range: 77 - 85
Received: Nov 15, 2021
Accepted: Dec 30, 2021
DOI: https://doi.org/10.2478/fco-2021-0011
Keywords
© 2021 Tanan Bejrananda et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Purpose
To explore clinical and pathological characteristics of testicular cancer and also identify factors associated with its oncological outcomes. Testicular cancer has a very good prognosis. Actually, we aim to report on 10 years of experience in the real-world practice of treating testicular cancer in a university-based hospital.
Methods
This is a retrospective cohort study of testicular cancer patients in Songklanagarind hospital; from January 2007 and December 2016, all eligible testicular cancer patients were included. Clinical characteristics (age, physical examination findings, tumour markers, histopathology, clinical stage, and initial treatment) and clinical outcomes were collected. These patients were divided into two groups: seminoma patients (seminomas) and non-seminoma patients (non-seminomas). Clinical characteristics and outcomes of treatment were analysed, and factors associated with oncological outcomes were identified.
Results
In 45 patients, median age 33 years, with diagnosis of testicular cancer, seminomas and non-seminomas were responsible for 23 (52.8%) and 22 (49%) of the cases, respectively. The median time of follow-up was 80.6 months (range: 1.8 to 120 months). The five-year OS was 94.7% and 57.1% in the seminoma and non-seminoma groups, respectively. For non-seminomas, five-year OS were 71.4%, 50%, and 42.9% in stage Ib–IIIa, IIIb, and IIIc, respectively, and for seminoma they were 92.3% and 100% in stage Ib–IIIa and IIIb, respectively. Multivariable analysis showed that non-seminoma, higher staging, and higher IGCCC risk were associated with poorer survival, significantly (
Conclusions
Seminoma has a good prognosis and survival at all stages, whereas, in the non-seminoma group, higher staging and IGCCC risk were independent factors associated with a poorer prognosis.